Pulmatrix (PULM) Common Equity (2013 - 2026)
Pulmatrix (PULM) posted Common Equity of $3.6 million for Q1 2026, down 5.75% sequentially from $3.8 million in Q4 2025, and down 49.76% YoY from $7.1 million in Q1 2025.
Pulmatrix (PULM) Common Equity (2013 - 2026) Analysis & Trends
Pulmatrix has reported Common Equity for 14 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Common Equity fell 49.76% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 49.76% YoY) and the FY2025 annual result came in at $3.8 million, down 57.42% from the prior year.
- Common Equity slipped to $3.6 million in Q1 2026 per PULM's latest filing, from $3.8 million in the prior quarter.
- Over five years, Common Equity peaked at $42.8 million in Q1 2022 and troughed at $3.6 million in Q1 2026.
- A 5-year average of $18.4 million and a median of $18.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity dropped 22.45% in 2022, then tumbled 62.42% in 2025.
- Over 5 years, Common Equity stood at $31.1 million in 2022, then tumbled by 42.16% to $18.0 million in 2023, then tumbled by 50.28% to $8.9 million in 2024, then sank by 57.42% to $3.8 million in 2025, then slipped by 5.75% to $3.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $3.6 million, $3.8 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.56 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 4.73 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 7.15 Mn |
| Dec 31, 2024 | 8.95 Mn |
| Sep 30, 2024 | 10.92 Mn |
| Jun 30, 2024 | 13.31 Mn |
| Mar 31, 2024 | 19.02 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Sep 30, 2023 | 19.88 Mn |
| Jun 30, 2023 | 23.45 Mn |
| Mar 31, 2023 | 27.01 Mn |
| Dec 31, 2022 | 31.11 Mn |
| Sep 30, 2022 | 35.05 Mn |
| Jun 30, 2022 | 38.44 Mn |
| Mar 31, 2022 | 42.76 Mn |
| Dec 31, 2021 | 47.45 Mn |
| Sep 30, 2021 | 45.19 Mn |